Liver Cancer

>

Latest News

Ten-fraction image-guided hypofractionated radiation therapy could be a feasible treatment option for portal vein tumor thrombosis in patients with HCC.
Hypofractionated RT Shows Portal Vein Tumor Thrombosis Control, OS in HCC

April 29th 2025

Ten-fraction image-guided hypofractionated radiation therapy could be a feasible treatment option for portal vein tumor thrombosis in patients with HCC.

SBRT Shows Positive 3-Year OS Rate in Newly Diagnosed Early-Stage HCC
SBRT Shows Positive 3-Year OS Rate in Newly Diagnosed Early-Stage HCC

April 26th 2025

MEV01 trial results show that the test achieved an 86% early-stage sensitivity and 88% specificity in surveillance of HCC among patients with cirrhosis.
FDA Grants EvoLiver Biopsy Test Breakthrough Device Designation for HCC

April 23rd 2025

FDA OKs Nivolumab/Ipilimumab in Unresectable/Metastatic HCC
FDA OKs Nivolumab/Ipilimumab in Unresectable/Metastatic HCC

April 11th 2025

Most recently, the FDA accepted a second NDA for camrelizumab/rivoceranib as a treatment for patients with unresectable HCC in October 2024.
FDA Issues Second Camrelizumab/Rivoceranib CRL in Hepatocellular Carcinoma

March 21st 2025

Video Series
Video Interviews
Podcasts
Govindarajan Narayanan, MD, speaks to the potential time-saving advantages of using the Epione robot for microwave ablation, cryoablation, and other surgical strategies in patients with liver cancer and other tumors.

More News